- Already a Sharekhan Customer? Login
- OPEN INSTAMF ACCOUNT
- OPEN TRADING ACCOUNT
|
Name of the Scheme Aditya Birla Sun Life Pharma & Healthcare Fund Scheme TypeAn open ended equity scheme investing in Pharma & Healthcare Services Sector |
 |
| Investment Manager Aditya Birla Sun Life |
Face Value Minimum Application Amount: Rs. 1000/- (Plus in multiple of Re. 1 thereafter) |
| Additional Purchase (Incl. Switch-in) Minimum Rs. 1000 (Plus in multiples of Re. 1 thereafter) |
Fund Manager Mr. Dhaval Shah |
| SIP Available during NFO and Ongoing offer period |
Benchmark S&P BSE Healthcare TRI |
| NFO Period 20 June, 2019 – 04 July, 2019 |
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
- A thematic fund investing in companies belonging to Pharma, Healthcare and other allied/ancillary sectors
- The portfolio while being largely focused on Pharma business, will also seek broader diversification by focusing on Wellness, Healthcare Services and Specialty Chemicals as well.
- The portfolio will be biased towards large caps & mid caps (60%-80%) & allocation to small cap companies will be 10%-20%.
- The fund can be suitable for long-term equity investors who have an investment horizon of 3-5 years at least.
The corpus of the Scheme will be primarily invested in equity and equity related securities of the companies in the Pharma & Healthcare Sector. The Scheme may also invest a small portion of its corpus in money market instruments to manage its liquidity requirements. All companies selected will be analysed taking into account the business fundamentals like nature and stability of business, prospects of future growth and scalability, financial discipline and returns, valuations in relation to broad market and expected growth in earnings, the company's financial strength and track record. The scheme may also invest in ADR/ GDR and equities of listed overseas companies. These investments will be made in line with the RBI and SEBI guidelines and will be within the limits prescribed by SEBI/RBI from time to time
The fund investment in debt securities and money market instruments issued by corporate and/or state and central government with the aim to controlling volatility and providing cash flows on a continuous basis. Rigorous in depth credit evaluation of the securities proposed to be invested in will be carried out by the investment team of the AMC for its fixed income investments. In addition, the Investment Team of the AMC studies the macro economic conditions, including the political, economic environment and factors affecting liquidity and interest rates.
The portfolio shall be structured so as to keep risk at acceptable levels and invest across Market cap. This shall be done through various measures including:
- Broad diversification of portfolio focusing on Pharma, Wellness, Healthcare Services and Specialty Chemicals*
- Ongoing review of relevant market, industry, sector and economic parameters
- Investing in companies which have been researched. Companies deemed to be leaders in their respective products/industry.
- High quality businesses exhibiting favorable economics, capable and trustworthy management teams
- Other parameters like operating profit margin, net profit margin, P/E ratio, better earnings visibility, etc.
- Investments in debentures and bonds will usually be in instruments which have been assigned investment grade ratings by any approved rating agency.
ABSLAMC may, from time to time, review and modify the Scheme’s investment strategy if such changes are considered to be in the best interests of the unitholders and if market conditions warrant it. Investments in securities and instruments not specifically mentioned earlier may also be made, provided they are permitted by SEBI/RBI and approved by the Trustee